This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Keloid scars

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Keloid scars are benign, but often disfiguring, tumour-like lesions that arise from the connective tissue elements of the skin. Classically, they are said to extend beyond the dimensions of the original wound or injury, grow relentlessly and are very refractory to treatment.

Wound healing progresses through three phases, inflammation, proliferation and remodelling. Keloids develop because of unchecked fibroblast growth and biosynthetic activity which starts during proliferation and progresses during maturation.

Keloids are distinct from hypertrophic scars. In the latter, the over-reactivity of the fibroblasts is ultimately checked and the scar hypertrophy remains within the boundaries of the original wound. There are thought to be other differences in their genetics, pathology, epidemiology and natural history (please see submenu).

Click here for an example image of this condition

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.